Business Description
Atara Biotherapeutics Inc
NAICS : 325412
SIC : 2836
ISIN : US0465131078
Total Employee Number:
13Description
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.83 | |||||
Equity-to-Asset | -1.87 | |||||
Debt-to-Equity | -0.27 | |||||
Debt-to-EBITDA | -1.84 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -140.15 | |||||
Beneish M-Score | -0.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -15.2 | |||||
3-Year FCF Growth Rate | 61 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 73.6 | |||||
9-Day RSI | 67.92 | |||||
14-Day RSI | 65.29 | |||||
3-1 Month Momentum % | 92.13 | |||||
6-1 Month Momentum % | -49.08 | |||||
12-1 Month Momentum % | 20.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.16 | |||||
Quick Ratio | 2.16 | |||||
Cash Ratio | 1.48 | |||||
Days Inventory | 4335.65 | |||||
Days Sales Outstanding | 53.33 | |||||
Days Payable | 344.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24 | |||||
Shareholder Yield % | 28.5 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 96.12 | |||||
Operating Margin % | -24.76 | |||||
Net Margin % | -40.91 | |||||
EBITDA Margin % | -23.69 | |||||
FCF Margin % | -111.1 | |||||
OCF Margin % | -111.1 | |||||
ROA % | -27.95 | |||||
ROIC % | -19.63 | |||||
3-Year ROIIC % | -316.81 | |||||
ROC (Joel Greenblatt) % | -42.79 | |||||
ROCE % | -42.71 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 58.13 | |||||
PS Ratio | 6.38 | |||||
EV-to-EBIT | -18.38 | |||||
EV-to-EBITDA | -19.55 | |||||
EV-to-Revenue | 4.63 | |||||
EV-to-Forward-Revenue | 206.78 | |||||
EV-to-FCF | -4.14 | |||||
Price-to-GF-Value | 7.58 | |||||
Earnings Yield (Greenblatt) % | -5.44 | |||||
FCF Yield % | -24.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Atara Biotherapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 19.988 | ||
| EPS (TTM) (€) | -0.666 | ||
| Beta | 1.1686 | ||
| 3-Year Sharpe Ratio | 0.11 | ||
| 3-Year Sortino Ratio | 0.21 | ||
| Volatility % | 174.13 | ||
| 14-Day RSI | 65.29 | ||
| 14-Day ATR (€) | 0.317802 | ||
| 20-Day SMA (€) | 8.9 | ||
| 12-1 Month Momentum % | 20.29 | ||
| 52-Week Range (€) | 3.48 - 16.3 | ||
| Shares Outstanding (Mil) | 9.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Atara Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Atara Biotherapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 09:00 | In 131 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 37 days | ||
| General meeting for 2026 | 2026-06-09 09:00 | 8.40 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 7.05 (+0.00%) | ||
| Annual report for 2025 | 2026-03-16 | 5.85 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 5.85 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 09:00 | 10.40 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-11 | 9.25 (+0.00%) | ||
| General meeting for 2025 | 2025-06-10 09:00 | 7.95 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 5.90 (+0.00%) |
Show
Entries
Atara Biotherapeutics Inc Frequently Asked Questions
What is Atara Biotherapeutics Inc(FRA:AT20)'s stock price today?
The current price of FRA:AT20 is €10.00. The 52 week high of FRA:AT20 is €16.30 and 52 week low is €3.48.
When is next earnings date of Atara Biotherapeutics Inc(FRA:AT20)?
The next earnings date of Atara Biotherapeutics Inc(FRA:AT20) is 2026-08-11 Est..
Does Atara Biotherapeutics Inc(FRA:AT20) pay dividends? If so, how much?
Atara Biotherapeutics Inc(FRA:AT20) does not pay dividend.
Press Release
Articles on Atara Biotherapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers